Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Synthomer plc is a leading business-to-business speciality chemicals producer, specializing in high-performance, highly specialised polymers and ingredients essential for key sectors including coatings, construction, adhesives, health and protection, performance materials, energy solutions, paper, carpet, foam, and consumer materials. These products enhance sustainability and performance in applications such as architectural coatings, mortar modification, waterproofing, flooring, tapes, labels, packaging, hygiene, tyres, medical gloves, and plastic modification, serving over 6,000 customers worldwide through 31 manufacturing sites and five innovation centres across Europe, the Americas, and Asia. Organised into three divisions—Coatings & Construction Solutions, Adhesive Solutions, and Health & Protection and Performance Materials—Synthomer plc addresses global megatrends like urbanisation, demographic change, climate change, and sustainability, with 59% of 2024 revenue from speciality products. Founded with roots tracing back to 1863 and rebranded in 2012, the company, headquartered in Harlow, Essex, UK, emphasises innovation, operational excellence, and portfolio management to deliver tailored, sustainable solutions that bind modern industries together.
£0.88
+£0.02 (+2.21%)
EOD Jul 3, 2026
Margins and capital returns are both well above average: 97.45% operating margin, ROIC at 72.00%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue declined 10.0% YoY. The question is whether this is cyclical or a structural shift.
Net debt of £629M represents 17.2x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£1.74B
▼ -10.0% YoY
Net Income (TTM)
-£157M
▼ -126.4% YoY
Op. Margin
97.45%
▼ -0.2pp YoY
ROIC
72.00%
▼ -1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
£37M
▲ +129.5% YoY
Op. Cash Flow (TTM)
£112M
▲ +624.5% YoY
Net Debt
£629M
Cash & Equiv.
£190M
3Y CAGR: -9.3%
3Y CAGR: -5.3%
Continue Research
Synthomer (SYNT.XLON) trades above a two-stage DCF intrinsic value of about £0.03 per share, so at £0.88 the stock looks overvalued (96.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Synthomer scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about £0.03 per share for SYNT.XLON, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around £0.03. At today's £0.88, that puts the stock about 96.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Synthomer scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 97.4% operating margin and a 72.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. SYNT.XLON currently trades above its estimated intrinsic value and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.